Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Talis Biomedical's share price is $2.84.
Talis Biomedical's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $0.17. Hence, Talis Biomedical's PS Ratio for today is 17.21.
The historical rank and industry rank for Talis Biomedical's PS Ratio or its related term are showing as below:
TLIS's PS Ratio is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.89 * Ranked among companies with meaningful PS Ratio only.
Talis Biomedical (OTCPK:TLIS) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Talis Biomedical PS Ratio Related Terms
Talis Biomedical PS Ratio Historical Data
* Premium members only.
The historical data trend for Talis Biomedical's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Talis Biomedical's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Talis Biomedical PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Talis Biomedical's PS Ratio distribution charts can be found below:
* The bar in red indicates where Talis Biomedical's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Talis Biomedical's Share Price of today is $2.84. Talis Biomedical's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.17.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Talis Biomedical (TLIS) has a PS Ratio of 17.21 as of Jul. 16, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Talis Biomedical and its competitors.
Is Talis Biomedical's PS Ratio too high?
Talis Biomedical's current PS Ratio is 17.21. The Medical Devices & Instruments industry median PS Ratio is 2.89. Talis Biomedical's value of 17.21 is 495.5% above this industry median. Overall, Talis Biomedical has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Talis Biomedical's PS Ratio compare to BJDX and BBLG?
Talis Biomedical's PS Ratio of 17.21 can be compared against companies in the Medical Devices & Instruments industry. The industry median PS Ratio is 2.89. Talis Biomedical's value of 17.21 is 495.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.89, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Talis Biomedical's current PS Ratio of 17.21 is 495.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Talis Biomedical and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Talis Biomedical's current PS Ratio is 17.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Talis Biomedical stock overvalued right now?
Talis Biomedical (TLIS) has a current PS Ratio of 17.21. The current PS Ratio is 17.21 and 495.5% above the Medical Devices & Instruments industry median of 2.89. Talis Biomedical's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Talis Biomedical (TLIS), the current PS Ratio is 17.21 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Talis Biomedical Corp is engaged in developing and commercializing products designed to enable molecular testing for infectious diseases and other conditions at the point-of-care. Its Talis One System is a molecular diagnostic platform developed to enable point-of-care testing for infectious diseases such as COVID-19.
28GF Score
Get the complete analysis for TLIS
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLIS has been successfully added to your 
